Catalyst Trusteeship, acting as Debenture Trustee, has created a pledge over 64,00,000 equity shares of OneSource Specialty Pharma, constituting 5.59% of the company’s total share capital. The pledge, created by Tenshi Pharmaceuticals in favor of the Debenture Trustee, secures debentures aggregating up to INR 1000,00,00,000. This action is in accordance with a debenture trust deed dated November 27, 2025.
Pledge Creation Details
Catalyst Trusteeship Limited, in its capacity as the Debenture Trustee, has announced the creation of a pledge on equity shares of OneSource Specialty Pharma Limited. The pledge involves 64,00,000 equity shares, representing 5.59% of the company’s issued and paid-up share capital.
Parties Involved
The Pledgor, Tenshi Pharmaceuticals Private Limited, has created the pledge in favor of Catalyst Trusteeship Limited, acting for the benefit of the holders of debentures. Karuna Ventures Private Limited, a group company of Tenshi Pharmaceuticals, has availed financial indebtedness by issuing debentures.
Debenture Details
The debentures are zero coupon, secured, unrated, unlisted, and redeemable non-convertible debentures, aggregating up to INR 1000,00,00,000. This arrangement is governed by a debenture trust deed dated November 27, 2025.
Share Pledge Agreement
The creation of the pledge aligns with the terms of a share pledge agreement also dated November 27, 2025. The agreement involves the Pledgor, the Issuer, and the Debenture Trustee, ensuring the debentures are secured by the specified equity shares.
Encumbrance Details
The Debenture Trustee now holds a pledge over the Pledged Shares, comprising 64,00,000 equity shares, which constitute 5.59% of the issued and paid-up share capital of OneSource Specialty Pharma. This pledge is for the benefit of the Debenture Holders, securing amounts payable under the Debenture Trust Deed and the Share Pledge Agreement.
Source: BSE
